[ad_1] Genetic medicines company Metagenomi Technologies said on Thursday it is aiming for a valuation of $563 million in its US initial public offering (IPO), a number that is at the low end of its initial target range. The company, backed by Moderna and Bayer Healthcare , plans to raise about $93.8 million by selling…
